成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
量少價(jià)低:抗生素行業(yè)將面臨重大危機(jī)

量少價(jià)低:抗生素行業(yè)將面臨重大危機(jī)

Megan Blewett, Bob Kocher, Bobby Shady 2019-11-19
創(chuàng)新抗生素的平均價(jià)格遠(yuǎn)低于其他治療領(lǐng)域的創(chuàng)新藥價(jià)格。

抗生素行業(yè)正在直線下滑,Achaogen和Tetraphase Pharmaceuticals等公司正在失去資金支持。圖片來源:Biomedical Imaging Unit, Southampton General Hospital/Science Photo Library—Getty Images Plus

今年6月,一批生物科技行業(yè)的代表人物匯聚舊金山。他們此行的目的是競購制藥公司Achaogen的資產(chǎn),后者于今年4月申請了破產(chǎn)保護(hù)。經(jīng)過一番商討和爭奪,最大的競購者以1600萬美元的價(jià)格帶走了Achaogen的幾乎所有資產(chǎn)。

一家制藥公司被迫關(guān)門本身未必是異常之事或者有新聞價(jià)值,但Achaogen并不是一個(gè)典型的生物科技公司破產(chǎn)事件。

2017年7月,Achaogen的市值還在10億美元以上(Venrock對Achaogen 投資的時(shí)間是2004年)。更重要的是,Achaogen已經(jīng)成功發(fā)現(xiàn)并開發(fā)出了一種針對嚴(yán)重抗藥性感染的抗生素,并且通過了美國食品與藥品監(jiān)督管理局(FDA)的審批。此外,該公司藥物是第一種獲得美國食品與藥品監(jiān)督管理局突破性療法認(rèn)定的抗生素。

與此同時(shí),在美國東海岸,設(shè)在波士頓的抗生素廠商Tetraphase在取得了類似成功后也開始陷入困境。和Achaogen一樣,Tetraphase開發(fā)的針對抗藥性細(xì)菌感染的抗生素也通過了美國食品與藥品監(jiān)督管理局的審批,這是一項(xiàng)壯舉。Tetraphase的市值也曾經(jīng)接近20億美元,但現(xiàn)在已經(jīng)跌至1000萬美元以下。

旨在推動抗生素創(chuàng)新的合作組織CARB-X的執(zhí)行董事凱文·奧特森在今年夏天曾經(jīng)向生物制藥網(wǎng)站發(fā)表聲明稱:“[抗菌劑]公司呈直線下滑狀態(tài),需要采取緊急行動來阻止這個(gè)行業(yè)的崩潰?!?/p>

雖然普通大眾越發(fā)意識到抗菌劑公司的麻煩正在不斷增大,但在生物科技領(lǐng)域以外,幾乎沒有人知道抗生素行業(yè)正在面臨著另一場商業(yè)危機(jī)。

為什么像Achaogen和Tetraphase這樣“成功”的抗生素公司發(fā)現(xiàn)自己在商業(yè)領(lǐng)域難以立足呢?歸根到底是新抗生素面臨的兩大問題:量少和價(jià)低。

第一個(gè)因素是量少,這在一定程度上和新抗生素的管理有關(guān)。在知道病人需要針對耐藥感染的抗生素前,醫(yī)生對于開這些新抗生素持有保留態(tài)度。此外,和其他許多藥物不同,大多數(shù)抗生素都需要添加到醫(yī)院的處方集中,而這需要院方進(jìn)行三到四輪的審核。結(jié)果就是新抗生素在上市的頭幾年中的銷量微乎其微。

第二個(gè)因素是價(jià)低,其原因是抗生素的報(bào)銷方式。在感染病人到醫(yī)院后,醫(yī)院會拿到一筆錢,被稱為診斷相關(guān)資金(DRG),其中包括病人在醫(yī)院接受的所有治療,包括開給他的抗生素。

要點(diǎn)在于,診斷相關(guān)資金中未使用的部分都會稱為醫(yī)院的利潤。這就促使醫(yī)院盡可能地使用平價(jià)抗生素。此外,這就意味著當(dāng)醫(yī)院選擇開非常貴的抗生素時(shí),通過診斷相關(guān)資金根本報(bào)銷不了,而醫(yī)院必然會出現(xiàn)虧損。

因此,創(chuàng)新抗生素的平均價(jià)格遠(yuǎn)低于其他治療領(lǐng)域的創(chuàng)新藥價(jià)格,而且大多數(shù)藥費(fèi)都不是通過診斷相關(guān)資金支付的。

受此影響,風(fēng)投資金對新抗生素的興趣不斷減弱。生物科技行業(yè)組織Biotechnology Innovation Organization的一項(xiàng)分析顯示,2009-2013年為開發(fā)創(chuàng)新抗生素投入的風(fēng)投資金總額約為6億美元。而在此期間,神經(jīng)藥物開發(fā)公司一共籌集了17億美元風(fēng)投資金,抗腫瘤藥制造商的風(fēng)投融資額為42億美元。

我們怎樣才能矯正這種動力上的偏差呢?可能方法之一是立法。2018年由民主、共和兩黨聯(lián)合提出的DISARM法案建議將抗生素排除在診斷相關(guān)資金之外。具體來說,該法案允許美國聯(lián)邦醫(yī)保向使用合格抗生素的醫(yī)院另行支付一筆錢。

民主、共和兩黨共同推出的另一項(xiàng)法案是REVAMP,其目的是向開發(fā)出新型重大抗生素的公司頒發(fā)證書,使其獲得更長的獨(dú)占權(quán)。隨后,另一家公司可以買下這樣的證書,以確保自身產(chǎn)品也有更長的獨(dú)占權(quán)。

可以用兒科優(yōu)先審核證書(針對兒科疾病的證書)來估算抗生素證書的價(jià)格;而且有很多兒科優(yōu)先審核證書的售價(jià)都超過了1億美元。

考慮到這些數(shù)字,一本這樣的證書實(shí)際上是一份現(xiàn)金獎勵,從而使抗生素開發(fā)公司不受獲批頭幾年銷售增長緩慢的影響。這段時(shí)期一家公司的支出通常會超過收入,這本證書則可以帶來關(guān)鍵的資金支持。

DISARM或REVAMP法案獲得通過都有可能極大地促進(jìn)新抗生素的開發(fā)。但不幸的現(xiàn)實(shí)是,目前對付耐藥性對兩黨來說都不是很緊迫的任務(wù)。市場力量讓開發(fā)新抗生素變得如此困難,而要出現(xiàn)改變市場力量的希望,就要先改變這種局面。

如果等式的一邊是調(diào)整市場,那么另一邊就是增加新的后備抗生素。美國食品與藥品監(jiān)督管理局的高級官員珍妮特·伍德科克對目前的后備抗生素的描述是“薄弱而且乏力”,這在很大程度上是因?yàn)樯衔恼劦降耐顿Y者不感興趣問題。

考慮到生物制藥的周期,后備產(chǎn)品薄弱會帶來特別大的問題,因?yàn)殚_發(fā)新藥的時(shí)間很容易就會達(dá)到甚至超過10年。

美國政府、健康和人類服務(wù)部(Department of Health and Human Services)以及CARB-X等行業(yè)組織正在資助公司推進(jìn)新抗生素的開發(fā)。CARB-X已經(jīng)從美國和英國政府以及維康信托基金會、比爾及梅琳達(dá)·蓋茨基金會等慈善組織手中獲得了約5億美元資金。

這筆資金非常關(guān)鍵,但實(shí)際上可能不夠多。要明白其中的理由,大家可以考慮一下,美國健康和人類服務(wù)部下屬的生物醫(yī)藥高級研發(fā)局(Biomedical Advanced Research and Development Authority)為Achaogen提供了近1.5億美元資金,目的是推動該公司的抗生素完成三期臨床實(shí)驗(yàn)。就連這種規(guī)模的政府資金也不足以讓這家公司在商業(yè)層面上生存下來。實(shí)際情況證明,量少和價(jià)低的組合問題極難解決。

為重新打造后備抗生素并應(yīng)對不斷增強(qiáng)的耐藥性,公司需要政府和非營利組織提供的資金。但這些資金還不夠。我們還必須修正市場,因?yàn)槭紫仁鞘袌鼋o抗生素開發(fā)帶來了如此巨大的挑戰(zhàn)。

如果新抗生素仍然以不合理的低價(jià)進(jìn)行報(bào)銷并且用在非常少的病人身上,開發(fā)這些藥在商業(yè)上仍然無法立足。非營利組織和政府支持這些公司的時(shí)間段可能不光是在爭取美國食品與藥品監(jiān)督管理局審批的過程中,它還包括獲得美國食品與藥品監(jiān)督管理局審批后收入微薄的那幾年。

這可能意味著政府要改變以往鼓勵藥物開發(fā)的模式,但實(shí)際情況也證明,抗生素獨(dú)具一格。無法及時(shí)解決這個(gè)問題就可能影響美國(乃至全世界)為下一輪嚴(yán)重抗藥性感染做好準(zhǔn)備。(財(cái)富中文網(wǎng))

梅根·布盧伊特是風(fēng)投公司Venrock的投資人。

鮑勃·柯歇爾是風(fēng)投公司Venrock的投資人、南加州大學(xué)謝弗衛(wèi)生政策和經(jīng)濟(jì)中心高級研究員以及斯坦福大學(xué)兼職教授。

鮑比·謝迪是醫(yī)療科技公司Renew Health的首席增長官。

譯者:Charlie

審校:夏林

This June, a group of biotech representatives converged on San Francisco. They had come to bid on the assets of pharmaceutical company Achaogen, which filed for Chapter 11 bankruptcy in April. When all was said and done, the top bidders walked away with virtually all of the company’s assets for $16 million.

A pharmaceutical company having to close its doors, in itself, is not necessarily uncommon or newsworthy. But Achaogen’s was not a typical biotech bankruptcy story.

As recently as July 2017, Achaogen had a market capitalization of over $1 billion. (Venrock invested in Achaogen in 2004.) More importantly, Achaogen had succeeded in discovering and developing an FDA-approved antibiotic to treat serious, drug-resistant infections. Furthermore, its drug was the first antibiotic to ever receive breakthrough therapy designation from the FDA.

Meanwhile, on the opposite coast, Boston-based antibiotic maker Tetraphase is now also struggling after a similar track record of success. Like Achaogen, Tetraphase has developed an FDA-approved antibiotic for drug-resistant bacterial infections—a herculean feat. It once boasted a market cap of nearly $2 billion but now sits at a market cap of under $10 million.

Kevin Outterson, executive director of CARB-X, a partnership dedicated to accelerating innovation in the antibiotic space, issued the following statement to Endpoints News this summer: “[Antimicrobial resistance] companies are in free fall and urgent action is needed to stop the collapse of the sector.”

While the general public is increasingly aware of the growing toll of antimicrobial resistance, few outside the biotech community are aware of this other, commercial crisis facing the antibiotic sector.

Why are “successful” antibiotics companies like Achaogen and Tetraphase finding themselves in commercially untenable situations? It boils down to two problems facing new antibiotics: low volumes and low price points.

The first driver, low volumes, is due in part to stewardship of new antibiotics; doctors are reticent to prescribe a new antibiotic for drug-resistant infections before they know patients need it. In addition, most antibiotics, unlike many other medicines, need to be added to hospital formularies, which can require three or four rounds of review from the hospital. The result can be negligible sales for the first several years after the launch of a new antibiotic.

The second factor, low price points, is the result of how antibiotics are reimbursed. When a patient is admitted to a hospital with an infection, the hospital receives a lump sum known as a diagnosis-related group (DRG) payment. This covers all the care the patient receives while admitted, including the antibiotics they are prescribed.

Importantly, any money under the DRG amount that the hospital does not spend is profit. This incentivizes hospitals to prescribe inexpensive antibiotics whenever possible. Furthermore, this means that when hospitals choose to prescribe a very expensive antibiotic, there is no way to get it reimbursed through the DRG and they are certain to lose money.

As a result, the price points for novel antibiotics are much lower on average than the price points for novel medicines in other therapeutic areas; most medicines are not paid for under a DRG.

In response, VC interest in new antibiotics has dwindled. According to an analysis by the Biotechnology Innovation Organization, a trade group representing the biotech industry, venture funding for companies developing novel antimicrobials totaled around $600 million from 2009 to 2013. During the same time period, companies developing neurology medicines raised a total of $1.7 billion in venture funding, and oncology companies secured $4.2 billion in venture investment.

How do we go about fixing this case of misaligned incentives? One possibility is legislation. The bipartisan DISARM Act, put forward in 2018, proposes to remove antibiotics from the DRG. Specifically, it would allow Medicare to offer an add-on payment to hospitals that use a qualifying DISARM antibiotic.

A second piece of bipartisan legislation, the REVAMP Act, aims to grant companies that develop crucial new antibiotics vouchers to extend their exclusivity. Another company could then buy that voucher to secure additional exclusivity for its own product.

Pediatric priority review vouchers (vouchers for conditions affecting children) can be used to estimate the price points one might achieve for antibiotics vouchers: A number of pediatric vouchers have sold for over $100 million.

Given these numbers, a voucher program would, in essence, provide a cash prize to allow the antibiotic developer to weather the slow sales uptake in the early years post-approval. This would provide critical funding during a period when a company’s spending typically exceeds its revenue.

Passage of either the DISARM Act or the REVAMP Act could significantly incentivize the development of new antibiotics. But the unfortunate reality is that—at the moment—combating antibiotic resistance is not a high priority for either political party. This needs to change if there is to be any hope of fixing the market forces that make it so challenging to develop new antibiotics.

If one side of the equation is fixing the marketplace, the other is bolstering our pipeline of new antibiotics. Senior FDA official Janet Woodcock has described the current antibiotic pipeline as “fragile and weak,” driven in large part by the lack of investor interest described above.

A weak pipeline is particularly problematic when one considers typical biopharma timelines: It can easily take 10 years or more to develop a new medicine.

Government and philanthropic groups like the Department of Health and Human Services (HHS) and CARB-X are funding companies to advance the development of new antibiotics. CARB-X has secured some $500 million in funding from the U.S. and U.K. governments and philanthropic organizations such as the Wellcome Trust and the Bill & Melinda Gates Foundation.

This money is critically important but—in reality—likely not sufficient. To understand why, consider this: Achaogen received nearly $150 million in funding from HHS’s Biomedical Advanced Research and Development Authority (BARDA) to progress its antibiotic through phase 3 clinical trials. Even this level of government funding was not enough to carry the company to commercial viability. The combination of low volumes and low price points proved insurmountable.

In order to rebuild our antibiotic pipeline and defend against mounting antibiotic resistance, companies will need capital from government and nonprofit organizations. But this funding is not enough. We must also fix the marketplace that has made antibiotic development so challenging in the first place.

If new antibiotics continue to be reimbursed at disproportionately low price points—and prescribed to a very small number of patients—developing these medicines will remain commercially untenable. Nonprofits and the government will likely need to support companies not only in the process leading up to FDA approval, but also in the years afterward when revenues are meager.

This would represent a shift in how the government has historically incentivized drug development, but antibiotics have proven to be in a class of their own. Failure to address this problem in a timely manner would undermine our country’s (and the world’s) preparedness for the next wave of serious, drug-resistant infections.

Megan Blewett is an investor at the venture capital firm Venrock.

Bob Kocher is an investor at Venrock, a senior fellow at the University of Southern California Schaeffer Center, and an adjunct professor at Stanford University.

Bobby Shady is the chief growth officer at Renew Health.

掃描二維碼下載財(cái)富APP
国产成人精品一区二三区在线观看| 久久亚洲精品中文字幕| 成年av卡通动漫精品一区| 亚洲成A∨人片在线观看无码| 一区二区三区日韩欧美在线观看| 亚洲精品高清在线观看| 大陆少妇无码在线观看| 亚洲av无码无限在线观看| 国产在线精品观看免费观看| 亚洲乱亚洲乱无码 | 国内丰满少妇一级毛片| 色翁荡息又大又硬又粗视频| 男人的天堂AⅤ一区二区| 欧美乱人伦人妻中文字幕| 久久国产劲暴∨内射新川| 手机在线观看亚洲国产精品| 伊人久久大香线蕉综合网站| 色中色综合欧美激情综合| 在线看片无码免费人成视频| 亚洲AV无码精品色午夜在线观看| 在线观看的黄网站免费| 人人欧美乱码专区视频免费看| 中文字幕人成乱码在线观看| 亚洲国产成人综合精品| 少妇午夜中文字幕无码无删减| 婷婷午夜天午夜福利综合| 国产日韩欧美综合色视频在线| 亚洲AV无码成人精品区在线播放| 国产内射999视频一区| 久热这里只精品99国产6| 久久国产精品男女热播| 亚洲日韩成人久久Av免费高清| 欧美亚洲国产一区二区三区| 亚洲午夜精品无码专区在线观看W| 蜜臀精品无码AV在线播放| 美国一级毛片片aa久久综合| 樱花官网官方进入入口| 国产成人精品一区二区三区免费看| 91校花国产大学生| 一区二区三区人妻无码| 14又嫩又紧水又多|